Faron Pharmaceuticals retained Stifel's 'buy' rating and €2.50 price target after its R&D day boosted confidence in bexmarilimab (BEX), a drug for high-risk myelodysplastic syndrome. While no major new efficacy data was disclosed, preliminary evidence suggests BEX may support normal bone marrow function. The upcoming BEXERA trial will test two doses of BEX with azacitidine against a control to confirm patient benefits, with first patient dosing expected in Q4 2026 and results by late 2027. Faron has €32 million cash, funding development through November 2027 but remains vulnerable to delays in recruitment or schedule changes.
Faron Pharmaceuticals is the subject of this update, with Pluang's Health sector data providing market context. Of 128 priced Health-sector US stocks tradable on Pluang, 66 rose and 52 fell today. Notable movers include INO at USD 1.14 (+4.59%), BIO at USD 375.02 (+4.06%), and SANA at USD 2.90 (+3.94%). This snapshot is as of Oct 09, 2026 17:11 WIB.
At Malaysia's IGEM 2026, Sigenergy showcased its latest AI-driven energy technologies, including smart storage and inverter systems, highlighting its role in advancing sustainable energy. The company also signed MOUs with local partners Milieu and YT...
NEAR Protocol traded at $4.93 on October 10, 2026, rising 8.6% after a sharp 16.37% drop the day before. Despite a 97.5% gain over 30 days, the price has been volatile and flat over the past two weeks, fluctuating within a narrow range. This volatili...
U.S. bitcoin spot ETFs reversed two days of outflows with $21.13 million in net inflows on October 9, 2026. Among 12 ETFs, IBIT and HODL attracted inflows of $22.38 million and $2.33 million respectively, while FBTC saw outflows of $3.58 million. The...
U.S. spot Ethereum ETFs experienced net outflows for the ninth consecutive trading day on October 9, with $56.1 million withdrawn, narrowing from $72.54 million the previous day. This streak began on September 29, reflecting ongoing investor caution ...
Two addresses on the Aster decentralized exchange (DEX) currently hold long positions totaling 7.2 million SYN tokens, valued at $1.34 million. These positions have unrealized gains of approximately $450,000, with the highest reported return reaching...
